8-K: Trevi Therapeutics Announces Third Quarter 2024 Financial Results and Clinical Program Updates

Trevi Therapeutics reported its Q3 2024 financial results, highlighted by increased R&D spending and progress in its clinical trials for Haduvio.

Summary

• Trevi Therapeutics announced its financial results for the third quarter of 2024, ending September 30, 2024.
• The company completed enrollment for the Phase 2a RIVER trial for refractory chronic cough (RCC) with topline results expected in the first quarter of 2025.
• They reached 50% enrollment in the Phase 2b CORAL trial for chronic cough in idiopathic pulmonary fibrosis (IPF), with a sample size re-estimation outcome expected in December 2024.
• Trevi ended the quarter with $65.5 million in cash, cash equivalents, and marketable securities, projecting a cash runway into the second half of 2026.
• Research and development expenses increased to $11.2 million in Q3 2024, up from $6.3 million in Q3 2023, due to increased clinical trial costs.
• General and administrative expenses rose to $2.9 million from $2.7 million in the same period last year, primarily due to increased stock-based compensation.
• The company reported a net loss of $13.2 million for the quarter, compared to a net loss of $7.7 million in the same period in 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is progress in clinical trials and a solid cash position, the increased net loss and R&D expenses are concerning. The sentiment is neutral to slightly negative due to the increased losses.

Positives

• The company has completed enrollment for the Phase 2a RIVER trial, which is a significant milestone.
• The company has a strong cash position of $65.5 million, which is expected to fund operations into the second half of 2026.
• The company has made progress in enrolling patients in the Phase 2b CORAL trial.
• The Human Abuse Potential (HAP) study has completed dosing.

Negatives

• The company's net loss increased to $13.2 million in Q3 2024, compared to $7.7 million in Q3 2023.
• Research and development expenses have significantly increased, indicating higher spending on clinical trials.
• General and administrative expenses have also increased, primarily due to stock-based compensation.

Risks

• The success of the clinical trials is uncertain, and positive data from one trial may not predict the results of later trials.
• Regulatory authorities' views on the clinical trial data and the development path for Haduvio are uncertain.
• The company's ability to fund future operations, including clinical trials, is subject to uncertainties.
• There are risks associated with estimating the company's cash runway, future expenses, and other financial results.

Future Outlook

The company anticipates topline results from the Phase 2a RIVER trial in the first quarter of 2025 and from the Phase 2b CORAL trial in the first half of 2025, assuming no adjustments to sample size. The company expects its current cash reserves to fund operations into the second half of 2026.

Management Comments

• Jennifer Good, President and CEO of Trevi Therapeutics, stated that the team has made excellent progress advancing clinical programs this year.
• Jennifer Good also mentioned that they are eagerly anticipating the upcoming clinical results starting in December.
• Management believes that positive results would bring them closer to addressing the unmet need and market opportunity in both chronic cough in IPF and RCC.

Industry Context

Trevi Therapeutics is focused on developing treatments for chronic cough, a condition with significant unmet medical needs, particularly in patients with IPF and RCC. The company's approach with Haduvio, targeting both central and peripheral cough mechanisms, is unique in the current landscape where there are no approved therapies for these conditions.

Comparison to Industry Standards

• Trevi's focus on chronic cough in IPF and RCC is a niche area with limited direct comparators, as there are no approved therapies for these specific indications.
• Other companies developing cough treatments, such as Bellus Health (acquired by GSK) with camlipixant, are targeting broader chronic cough populations, not specifically IPF or RCC.
• The increase in R&D spending is typical for a clinical-stage biotech company advancing multiple trials, and the cash runway into the second half of 2026 is a positive sign for funding these activities.
• The net loss is also typical for a company at this stage, as they are investing heavily in clinical development without revenue-generating products.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and R&D expenses.
• Employees may be encouraged by the progress in clinical trials and the company's financial stability.
• Patients with IPF and RCC may be hopeful for the potential of Haduvio to address their unmet medical needs.
• Creditors may be reassured by the company's cash runway into the second half of 2026.

Next Steps

• The company will release the sample size re-estimation (SSRE) outcome for the CORAL trial in December 2024.
• Topline results from the Human Abuse Potential (HAP) study are expected in December 2024.
• Topline results from the Phase 2a RIVER trial are expected in the first quarter of 2025.
• Topline results from the Phase 2b CORAL trial are expected in the first half of 2025, assuming no adjustments to sample size.
• The company plans to participate in the Stifel 2024 Healthcare Conference on November 18-19 and the Piper Sandler 36th Annual Healthcare Conference on December 3-5.

Key Dates

Keywords

Trevi Therapeutics, Haduvio, Chronic Cough, Idiopathic Pulmonary Fibrosis, Refractory Chronic Cough, Clinical Trials, RIVER trial, CORAL trial, Nalbuphine ER, Biopharmaceutical